Zvinetso varwere vegomarara rechiropa vanofanirwa kubata nazvo

Share This Post

There are usually many problems that patients with liver cancer need to deal with, mainly including the following aspects:

1) To deal with the side effects of the body, most treatments for liver cancer will produce some side effects accordingly. Sometimes, the side effects can continue after the treatment is completed, and the doctors call them long-term side effects. Treatment of long-term side effects and late effects is an important part of survival care. Doctors will strive to prevent and alleviate the side effects of gomarara rechiropa patients. This kind of treatment belongs to the category of “palliative treatment”. Regardless of the patient’s age and disease stage, it is an important part of the treatment plan.

2) Coping with emotional and social impacts, after cancer diagnosis, will have a certain impact on patients’ emotional and social relationships and the body. Including negative emotions, such as sadness, anxiety or anger, stress, etc. Sometimes patients have problems expressing their feelings to their loved ones, or people do n’t know how to respond. At this time, patients and their families share their feelings with the doctor as much as possible.

3) In response to financial implications, cancer treatment can be expensive. It is often an important source of stress and anxiety for cancer patients and their families. In addition to the cost of treatment, many people find that they have everything related to their care. For some people, the high cost prevents them from following or completing their cancer treatment plan. This requires patients and families to come up with coping strategies, including combining other available resources to solve financial problems.

Subscribe To Newsletter Vedu

Wana zvigadziriso uye usambopotsa blog kubva kuCancerfax

Zvimwe Kuti Uongorore

Lutetium Lu 177 dotatate inotenderwa neUSFDA kune vana vane makore gumi nemaviri zvichikwira neGEP-NETS.
kenza

Lutetium Lu 177 dotatate inotenderwa neUSFDA kune vana vane makore gumi nemaviri zvichikwira neGEP-NETS.

Lutetium Lu 177 dotatate, kurapwa kwepasi, ichangobva kugamuchira mvumo kubva kuUS Food and Drug Administration (FDA) yevarwere vevana, zvichiratidza chiitiko chakakosha muvana oncology. Mvumo iyi inomiririra chiedza chetariro kuvana vari kurwisana neuroendocrine tumors (NETs), isingawanzowanikwi asi inonetsa yegomarara iro rinowanzoratidza kuti rinoshingirira pakurapa kwakajairika.

Nogapendekin alfa inbakicept-pmln inotenderwa neUSFDA yeBCG-isingapindure isiri-muscle invasive cancer cancer.
Chirwere chechirwere

Nogapendekin alfa inbakicept-pmln inotenderwa neUSFDA yeBCG-isingapindure isiri-muscle invasive cancer cancer.

"Nogapendekin Alfa Inbakicept-PMLN, chinyorwa che immunotherapy, chinoratidza vimbiso mukurapa gomarara redundira kana yasanganiswa neBCG therapy. Iyi nzira yekuvandudza yakanangana nemakaki egomarara uku ichisimudzira mhinduro ye immune system, ichiwedzera kushanda kwemishonga yechivanhu seBCG. Miedzo yemakiriniki inoratidza zvinokurudzira, zvichiratidza zvakavandudzwa mhedzisiro yemurwere uye kufambira mberi kunogona kuitika mukurapa kenza yedundira. Kuwirirana pakati peNogapendekin Alfa Inbakicept-PMLN neBCG kunozivisa nguva itsva mukurapa gomarara redundira.

Kuda rubatsiro? Chikwata chedu chakagadzirira kukubatsira.

Tinoshuvira kupora nekukurumidza kwemudiwa wako uye padyo neuyo.

Kutanga kutaura
Tiri paIndaneti! Taura Nesu!
Skena kodhi
Mhoro,

Kugamuchirwa kuCancerFax!

CancerFax ipuratifomu yekupayona yakatsaurirwa kubatanidza vanhu vakatarisana negomarara repamberi nekurapa kwesero seCAR T-Cell therapy, TIL kurapwa, uye miedzo yekiriniki pasi rese.

Tizivise zvatinogona kukuitira.

1) Kurapwa kwegomarara kunze kwenyika?
2) CAR T-Cell therapy
3) Mushonga wegomarara
4) Online vhidhiyo kubvunza
5) Proton kurapwa